That's where LMNT may have an advantage
No phone or Wi-Fi setup
The addition of glucagon produced approximately 25-30% more weight loss than dual agonism
The organization stated counterfeit medications were entering the U.S
Consumers Taking GLP-1s for Weight Loss, Current or Discontinued, Drive Lasting Changes in Retail, Per New Acosta Group Study News provided by Acosta Group Apr 14, 2025, 12:05 ET 76% of those who discontinued GLP-1s are eating the same amount or less and many report retaining healthy habits JACKSONVILLE, Fla., April 14, 2025 /PRNewswire/ -- In advance of the National Association of Chain Drug Stores (NACDS) Annual Meeting, Acosta Group is sharing the results of its recent proprietary GLP-1 Shopper Community study, focusing on consumers using the medications specifically to support weight loss
A novel dual agonist of glucagon-like peptide-1 receptors and neuropeptide Y2 receptors attenuates fentanyl taking and seeking in male rats